INTRODUCTION
Ralo xifene hydrochloride 1 ( Figure 1 ) belongs to the benzothiophene class of compound and it is currently used for prevention of osteoporosis in postmenopausal women. It was approved by Food and Drug Administration (FDA) in 1997. Chemically it is 6-Hydro xy -2-(4-hydro xy phenyl) benzo {b} thien-3-y l] [4-{2-(1-piperid inyl)-ethoxy }-phenyl] methanone with a mo lecular weight 510.05 g/mo l. It binds to the nuclear estrogen receptors (ERα and ERß) and either activates or blocks ER-induced gene transmission, depending on the tissue involved. Ralo xifene hydrochloride demonstrates estrogen agonist effects on bone and blood lipid levels wh ile it is a competitive antagonist of estrogen at mammary and uterine estrogen receptors [2] [3] . Ralo xifene hydrochloride is cardio protective, in part due to its effects on plasma lipid d istribution. Like estradiol, ralo xifene hydrochloride reduces total and lowdensity lipoprotein (LDL) levels in p lasma. Ho wever, unlike estradiol, it does not increase plasma high-density lipoprotein (HDL) and triglyceride levels in plasma 4 . There are also some adverse effects, namely increased incidences of hot flushes and in low percentage venous thromboembolic events 5 .
Figure 1: Chemical S tructure of Raloxifene Hydrochloride
Analytical methods described in literature for the determination of Ralo xifene hydrochloride in biological and other matrices involve spectrophot omet ry [6] [7] [8] [9] [10] [11] [12] [13] , liquid chromatography [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , cap illary elect rop ho res is 31 and reso nan ce ray leigh scattering 32 .
Quality control of pharmaceutical products requires identification and quantification of the active ingredient and its impurities for safety and efficacy reasons . Impurit ies and potential degradation products that may exist in med icines can change the chemical, pharmacological and toxico logical properties of the product. Since pharmacopoeias do not describe a suitable method for the determination of Ralo xifene hydrochloride in pharmaceutical formu lations, in the present work we developed simple, rap id and accurate reverse phase liquid chromatographic method for the determination of Ralo xifene hydrochloride in tablets.
MATERIALS AND METHODS

Chemicals and Reagents
Ralo xifene Hydrochloride standard (purity 99.80%) was obtained from M/S BA L Pharma, India. Methanol (HPLC grade), sodium acetate , glacial acetic acid , sodium hydroxide (NaOH), hydrochloric acid (HCl) and hydrogen peroxide (H 2 O 2 ) were obtained fro m Merck , Ind ia. HPLC grade water was obtained from Merck, India. The drug products of Ralo xifene Hydrochloride, i.e. RA LISTA ® (Cipla Ltd. India), FIONA ® (Dr. Reddy's Laboratories Ltd. India), RA LOCIUM ® (Bal Pharma Ltd., India) available as tablets (Label claim 60.0 mg ) were procured fro m the pharmacy store and all other chemicals were of an analytical grade and used as received.
Instrumentation
Chro matographic separation was achieved by using a Shimad zu Model CBM-20A/20 A lite HPLC system, equipped with SPD M 20A pro minence photodiode array detector (250 mm × 4.6 mm, 5 µm particle size) maintained at 25 ºC.
Chromatographic Condi tions
Isocratic elution was performed using sodium acetate: methanol (40:60, V/ V) as mobile phase with a flow rate of 1 mL/ min. UV detection was performed at 287 n m.
Preparation of Raloxifene hydrochlori de Stock Solution
Ralo xifene hydrochloride stock solution (1000 μg/mL) was prepared by accurately weighing 25 mg of Ralo xifene hydrochloride in a 25 mL amber volu metric flask and making up to volume with methanol. Working solutions for HPLC in jections were prepared on a daily basis from the stock solution in a solvent mixture of sodium acetate: methanol (40:60, V/ V) (mobile phase). Solutions were filtered through a 0.45 μm membrane filter prior to injection and 20 µL was in jected into the HPLC system.
Preparation of Sample Solutions
Twenty tablets from each brand (RALISTA ® and RA LOCIUM ® ) were procured, weighed and crushed to a fine powder. Powder equivalent to 25 mg Ralo xifene hydrochloride was accurately weighed into a 25 ml volumetric flask and made up to volume with mobile phase. The contents of the volumetric flask were sonicated for 30 min to enable complete dissolution of Ralo xifene hydrochloride. The solution was filtered and the filtrate was diluted with mobile phase. 20 μL of these solutions were injected into the system and the peak area was recorded fro m the respective chromatogram.
Forced Degradation Studies/Specificity
The study was intended to ensure the effective separation of Ralo xifene hydrochloride and its degradation peaks of formulat ion ingredients at the retention time of Ralo xifene hydrochloride. Separate portions of drug product and ingredients were exposed to the follo wing stress conditions to induce degradation. Forced degradation studies were performed to evaluate the stability indicat ing properties and specificity of the method 33 . All solutions for use in stress studies were prepared at an initial concentration of 1 mg / mL of Ralo xifene hydrochloride and kept at room temperature for 30 min. A ll samples were then diluted in mobile phase to give a final concentration of 50 μg/ mL and filtered before inject ion.
Aci dic and Alkaline Degradati on
Ralo xifene hydrochloride drug solution (1.0 mg/ mL) was treated with 0.1 M HCl and kept at room temperature for 30 min and then the stressed sample was neutralized and diluted with mobile phase to give a final concentration of 50 μg/ mL and filtered before injection.
Similarly stress studies in alkaline conditions were conducted by exposing the drug sample solution with 0.1 M NaOH for 30 min at room temperature and then the stressed sample was neutralized and diluted with mobile phase to give a final concentration of 50 μg/ mL and filtered before inject ion.
Oxi dati ve Degradati on
Solutions for oxidative stress studies were conducted by treating the drug solution with 3% H 2 O 2 for 30 min at room temperature and then diluted with mobile phase to give a final concentration of 50 μg/mL.
Photol ytic Degradati on
The drug solution (1 mg/mL) for photo stability testing was exposed to UV light for 4 hours in a UV light chamber (365 n m) and diluted with the mobile phase to give a final concentration of 50 μg/ mL and filtered before inject ion.
Method Vali dation
The method was validated for the following parameters: system suitability, linearity, limit of quantitation (LOQ), limit of detection (LOD), precision, accuracy, selectivity and robustness 34 .
Linearity
Linearity test solutions for the assay method were prepared fro m a stock solution at different concentration levels of the analyte (1.0-250 µg/mL). 20 µL of each solution was injected in to the HPLC system and the peak area of the chromatogram obtained was noted. The solutions extracted fro m the marketed formulat ions were injected in to the HPLC system and the peak area of the chro matograms was noted. The analytical curve was evaluated on three different days. The peak area vs. concentration data was analyzed with least squares linear regression. The slope and y-intercept of the calibration curve was reported.
Precision
The intra-day precision of the assay method was evaluated by carrying out 9 independent assays of a test sample of Ralo xifene hydrochloride at three concentration levels (10, 50 and 100 µg/ mL) (n=3) against a qualified reference standard. The %RSD of three obtained assay values at three different concentration levels was calculated. The interday precision study was performed on three different days i.e. day 1, day 2 and day 3 at three different concentration levels (10, 50 and 100 µg/ mL) and each value is the average of three determinations (n=3). The % RSD of three obtained assay values on three different days was calculated.
Accuracy
The accuracy of the assay method was evaluated in triplicate at three concentration levels (80, 100 and 120%), and the percentage recoveries were calcu lated. Standard addition and recovery experiments were conducted to determine the accuracy of the method for the quantification of Ralo xifene hydrochloride in the drug product. 
Sensitivity/ Li mit of quanti ficati on (LOQ) and limit of detection (LOD)
The limit of quantification (LOQ) and limit of detection (LOD) were based on the standard deviation of the response and the slope of the constructed calibration curve (n=3), as described in International Conference on Harmonizat ion guidelines Q2 (R1) 34 . Sensitivity of the method was established with respect to limit of detection (LOD) and LOQ fo r Ralo xifene hydrochloride. LOD and LOQ were established by slope method as mentioned below. 
LOD
Solution Stability and Mobile Phase Stability
The solution stability of Ralo xifene hydrochloride in the assay method was carried out by leaving both the sample and reference standard solutions in tightly capped volumetric flasks at roo m temperature for 48 h. The same sample solutions were assayed at 12 h intervals over the study period. The mobile phase stability was also assessed by assaying the freshly prepared sample solutions against freshly prepared reference standard solutions at 12 h intervals up to 48 h. The prepared mob ile phase remained constant during the study period. The % RSD of the Ralo xifene hydrochloride assay was calculated for the mobile phase and solution stability experiments. An additional study was carried out using the stock solution by storing it in a t ightly capped volumetric flask at 4 ºC.
RES ULTS AND DISCUSS ION
The present proposed method is simple, precise, accurate and is applicable for a wide linearity range in co mparison to the reported methods in the literature. A reversed-phase chromatographic technique was developed to quantitate Ralo xifene hydrochloride at 287 nm. Methanol was chosen as an organic modifier in the mobile phase. Satisfactory resolution was achieved with use of a mixture of sodium acetate: methanol (40:60, V/ V) as mobile phase with a flow rate of 1 ml/ min as demonstrated in Figure 2 . C18 column was adopted for the analysis because it provided a better separation of the analytes. The present method is a stability indicating RP-HPLC method which was not reported earlier. The present stability-indicat ing method for the determination of Ralo xifene hydrochloride in pharmaceutical formulat ions is specific because the drug peak was well separated even in the presence of degradation products. Overall, the data demonstrated that the e xcip ients and the degradation products did not interfere with the Ralo xifene hydrochloride peak, indicating the selectivity of the method. The complete separation of the analytes was accomplished in less than 10 min and the method can be successfully applicable to perform long-term and accelerated stability studies of Ralo xifene hydrochloride fo rmulat ions.
HPLC Method Devel opment and Opti mization
Initially the stressed samples were analyzed using a mobile phase consisting of water: acetonitrile (60:40, v/v) at a flow rate of 1.0 mL/ min. Under these conditions, the resolution and peak symmetry were not satisfactory, so the mobile phase was changed to sodium acetate: methanol (40:60, V/ V) with a flow rate of 1 ml/ min under which peaks were well resolved with good symmetry and sharpness. Therefore, mobile phase containing sodium acetate: methanol (40:60, V/ V) ml/ min was chosen as the best chromatographic response for the entire study.
Method Vali dation
System Suitability
The system suitability test was performed to ensure that the complete testing system was suitable for the intended application. The parameters measured were peak area, retention time, tailing factor, capacity factor and theoretical plates. In all measurements the peak area varied less than 2.0%, the average retention time was 5.1 ± 0.05 minutes. The capacity factor was more than 2, theoretical plates were 9976 (mo re than 2000) and tailing factor was 1.21 (less than 2) for the Ralo xifene hydrochloride peak. The proposed method offers high sensitivity and Ralo xifene hydrochloride can be detected accurately. In all © 2011, JDDT. All Rights Reserved ISSN: 2250-1177 CODEN (USA): JDDTAO the cases, the Ralo xifene hydrochloride peak was well separated fro m the degradation products.
Linearity
The calibration curve for Ralo xifene hydrochloride was linear over the concentration range of 1.0-250 μg/ mL. The linearity data was given in Tab le 1. A calibration curve was drawn by taking the concentration on the x-axis and the corresponding peak are on the y-axis. The regression equation was found to be y = 95604 x -26215 with correlation coefficient 0.9999.
Figure 3: Calibration Curve of Raloxifene hydrochloride Precision
The precision of the method was determined by repeatability (Intra-day precision) and intermediate precision (Inter-day precision) of the Ralo xifene hydrochloride standard solutions. Repeatability was calculated by assaying three samples of each at three different concentration levels (10, 50 and 100 µg/ mL) on the same day. The inter-day precision was calculated by assaying three samples of each at three different concentration levels ((10, 50 and 100 µg/ mL) on three different days. The % RSD range was obtained as 0.16-0.54 and 0.17-0.53 for intra-day and inter-day precision studies respectively (Table 2) . Because the stability of standard solutions can also affect the robustness of analytical methods, the stability of standard solutions of the drug substance used in this method was tested over a long period of time. One portion of a standard solution was kept at room temperature and the other portion was stored under refrigeration at approximately 4ºC and the content of these solutions was regularly co mpared with that of freshly prepared solutions. No change in drug concentrations were observed for solutions stored under refrigeration. But it is recommended that the sample and standard solutions be freshly prepared in amber co lored flasks to protect from light.
Accuracy
The method accuracy was proven by the recovery test. A known amount of Ralo xifene hydrochloride standard (10 μg/mL) was added to aliquots of samples solutions and then diluted to yield total concentrations as 18, 20 and 22 μg/mL as described in Table 3 . The assay was repeated over 3 consecutive days. The resultant % RSD was 0.27 (<2.0 %) with a recovery 99.40-99.9 %. 
Li mit of Detection and Li mit of Quantification
The LOQ and LOD were determined based on the 10 and 3.3 times the standard deviation of the response, respectively, divided by the slope of the calibration curve. The LOD and LOQ were found to be 0.267 μg/ mL and 0.813 μg/mL respectively.
Selectivity/Specificity
The specificity of the developed method was determined by injecting sample solutions (50 μg/mL) wh ich were prepared by forcibly degrading under such stress conditions as heat, light, o xidative agent, acid and base under the proposed chromatographic conditions. The stability indicating capability of the method was established from the separation of Ralo xifene hydrochloride peak fro m the degraded samples derived fro m the software. The degradation of Ralo xifene hydrochloride was found to be very similar for both the tablets and standard.
Solution Stability and Mobile Phase Stability
The %RSD of the assay of Ralo xifene hydrochloride fro m the solution stability and mobile phase stability experiments was within 2%. The results of the solution and mobile phase stability experiments confirm that the sample solutions and mobile phase used during the assays were stable up to 48 h at room temperature and up to 3 months at 4ºC.
Analysis of Commercial Formulations (Tablets)
The proposed method was applied to the determination of Ralo xifene hydrochloride tablets RALISTA ®, FIONA ® and RALOCIUM ® and the result of these assays yielded 99.96-100.04 % respectively with RSD < 2.0 %. The result of the assay (Table 4) indicates that the method is selective for the assay of Ralo xifene hydrochloride without interference fro m the excip ients used in these tablets . The typical chromatograms for Ralo xifene hydrochloride obtained fro m the extracted marketed fo rmu lations were shown in Figure 4a and 4b. 
Forced Degradation Studies
Ralo xifene hydrochloride standard and tablet powder was found to be quite stable under dry heat conditions. Typical chromatograms obtained following the assay of stress ed samples are shown in Figure 5a -5d. A very slight decomposition was seen on exposure of Ralo xifene hydrochloride drug solution to acidic (2.52), alkaline (3.35) and oxidation (2.53). During the oxidative degradation one major degradant was observed at 2.734 mins without interfering the elution of drug peak (5.015 mins) and the percentage of drug decomposition was found to be 2.53 % indicat ing that the drug is highly resistant towards oxidation. Ralo xifene hydrochloride has undergone photo degradation (1.52) very slightly i.e. less than 2.0 %. Table 5 summarizes the data of degradation studies.
CONCLUS ION
The proposed stability-indicat ing HPLC method was validated as per ICH guidelines and applied for the determination of Ralo xifene hydrochloride in pharmaceutical dosage forms. The method was found to be accurate, precise, robust and specific as the drug peak did not interfere with the ext ra peaks aroused during the forced degradation studies. At the same time the chromatographic elution step is undertaken in a short time (< 6 min). No interference fro m any components of pharmaceutical dosage form or degradation products and therefore the method can be successfully applied to perform long-term and accelerated stability studies of Ralo xifene hydrochloride formu lations. In conclusion, the h igh sensitivity, good selectivity, accuracy and reproducibility of the proposed method is suitable for quality control analysis of complex pharmaceutical preparation containing Ralo xifene hydrochloride. The reduction of acetonitrile consumption is one of the best solutions to the current global acetonitrile shortage and will safeguard against future risk.
